Following bispecific deal with Pfizer, quiet California biotech raises $65M, heads to the clinic

At the beginning of the year, Dren Bio penned a deal with Pfizer for a potential $1 billion for its bispecific antibody platform. The details …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Fol­low­ing bis­pe­cif­ic deal with Pfiz­er, qui­et Cal­i­for­nia biotech rais­es $65M, heads to the clin­ic